- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00913328
Effect of Add-on Montelukast to Inhaled Corticosteroids on Airway Responsiveness (SINGDEN)
Effect of Add-on Montelukast to Inhaled Corticosteroids in Excessive Airway Narrowing in Adults With Asthma
Leukotriene receptor antagonists appear to posses additive anti-inflammatory effects to the effect of inhaled corticosteroids.
Hypothesis: Treatment with oral montelukast will lower the dose-response plateau to inhaled methacholine in patients with mild to moderate persistent asthma treated with a stable dose of inhaled corticosteroids.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Non-smoking adults with mild to moderate persistent asthma:
- FEV1 > 70 % pred
- PD20 methacholine < 3.9 mmol
- treated for at least 3 months with a stable dose of inhaled corticosteroids
- Documented dose-response plateau to inhaled methacholine on two occasions
- Males and non-pregnant females
Exclusion Criteria:
- Asthma medication other than inhaled corticosteroids and inhaled b2-agonists
- Viral respiratory tract infections within the 3 weeks prior to enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Montelukast
Oral montelukast 10 mg once daily for 12 weeks
|
10 mg tablet once daily
Other Names:
|
Placebo Comparator: Placebo
Oral placebo once daily for 12 weeks
|
Oral placebo once daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes from baseline in maximal FEV1 decline at the dose-response plateau
Time Frame: After 12 weeks of treatment
|
After 12 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes from baseline in PD20 methacholine
Time Frame: After 12 weeks of treatment
|
After 12 weeks of treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Zuzana Diamant, MD, PhD, Erasmus Medical Center
- Principal Investigator: Charlotte S Ulrik, MD, DMSc, Dept. of Heart and Lung Diseases, Hvidovre Hospital, Denmark
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Anti-Asthmatic Agents
- Respiratory System Agents
- Leukotriene Antagonists
- Hormone Antagonists
- Cytochrome P-450 CYP1A2 Inducers
- Cytochrome P-450 Enzyme Inducers
- Montelukast
Other Study ID Numbers
- SINGDEN-04-2002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on Montelukast (Singulair)
-
Indiana UniversityCompleted
-
Mayo ClinicMerck Sharp & Dohme LLCCompleted
-
CHA UniversityMerck Sharp & Dohme LLCCompleted
-
Nemours Children's ClinicMerck Sharp & Dohme LLCCompleted
-
The First Affiliated Hospital of Guangzhou Medical...Merck Sharp & Dohme LLCUnknown
-
University of New MexicoAmerican College of Clinical PharmacyCompleted
-
Shanghai Jiao Tong University School of MedicineShanghai General Hospital, Shanghai Jiao Tong University School of MedicineCompleted
-
Torrent Pharmaceuticals LimitedCompleted
-
Murdoch Childrens Research InstituteMonash UniversityCompletedDermatitis, AtopicAustralia
-
Dr. Reddy's Laboratories LimitedCompleted